{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Graded using the Glucksberg scale. Proportions and confidence intervals will be estimated. Estimated using binary proportion estimates as well as competing risk method.","groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.\n\nGVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.\n\nanti-thymocyte globulin : Given IV\n\npharmacological study : Correlative studies\n\nfludarabine phosphate : Given IV\n\nbusulfan : Given IV\n\nbortezomib : Given IV\n\nallogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT\n\ntacrolimus : Given IV\n\nlaboratory biomarker analysis : Correlative studies\n\nsirolimus : Given PO","id":"OG000","title":"Treatment (Chemotherapy, Enzyme Inhibitor)"}],"populationDescription":"Data was not collected, because funding was unavailable to continue study.","reportingStatus":"POSTED","timeFrame":"First 6 months post-transplant","title":"Incidence and Severity of Acute GVHD Using Fludarabine Phosphate / Busulfan / Bortezomib Preparative Regimen and Triple Immune Suppression With Tacrolimus, Sirolimus and Anti-thymocyte Globulin","type":"PRIMARY"}